4 completed, 2 not yet recruiting, 1 active not recruiting, 1 withdrawn. 8 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Not yet recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Not yet recruiting 2, Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow PENTA Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl) - HIV -1 Infection | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario 12 de Octubre | 87 | 2027-01-01 | 2026-08-20 |
| Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2) Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl), Broadly neutralizing antibody (bNAb) VRC07-523-LS - HIV -1 Infection | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario 12 de Octubre | 73 | 2027-01-01 | 2026-08-20 |
| Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV DRV/r FDC (120/20mg) - HIV Infections | Phase 1 / Phase 2 | Withdrawn | PENTA Foundation | 2025-02-01 | 2026-03-05 | |
| Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance Fostemsavir - HIV Infections With Multi Drug Resistant Virus | Phase 1 / Phase 2 | Active not recruiting | PENTA Foundation | 60 | 2022-06-30 | 2026-03-05 |
| Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth HIVIS DNA/MVA-CMDR, HIVIS DNA + Cervarix and MVA-CMDR, Cervarix - HIV Infections | Phase 1 | Completed | Henry M. Jackson Foundation for the Advancement of Military Medicine | 25 | 2022-02-18 | 2025-08-11 |
| Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis Meropenem - Meningitis | Phase 1 / Phase 2 | Completed | PENTA Foundation | 51 | 2013-02-01 | 2015-02-16 |
| PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months Intervention 1: PK assessment while on Twice Daily Abacavir, Intervention 2: PK assessment while on Once Daily Abacavir - HIV Infection | Phase 1 | Completed | PENTA Foundation | 23 | 2006-07-01 | 2014-03-20 |
| Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children ABC Twice Daily, ABC Once Daily, 3TC Once Daily - HIV Infection | Phase 1 | Completed | PENTA Foundation | 19 | 2003-01-01 | 2013-11-13 |
HIV Infections (4) · Meningitis (1)
Broadly Neutralizing Antibodies (2) · Sodium Chloride (2) · Meropenem (1) · abacavir (1) · fostemsavir (1) · human papillomavirus vaccine, L1 type 16, 18 (1)
United Kingdom (3) · South Africa (2) · Brazil (1) · Cameroon (1) · France (1) · Germany (1) · Italy (1) · Senegal (1) · Spain (1) · Uganda (1) · United States (1) · Zimbabwe (1)
Albert Faye (1) · Hermione Lyall, MD (1) · Merlin Robb, MD (1) · Vas Novelli, MD (1)
2005 (1)